Rabbit monoclonal antibodies are paving the way in the fight against Parkinson’s disease by accelerating research through targeting key Parkinson’s disease proteins.
The Michael J. Fox Foundation (MJFF) reached out to Abcam to collaborate on the development of new tools for Parkinson’s disease research, such as rabbit monoclonal antibodies for leucine-rich repeat kinase (LRRK2), alpha-synuclein, DJ-1, RAB8A, and RAB10. MJFF is established with the goal of finding a cure for Parkinson’s disease as well as promoting improved therapies for those living with the disease today.
Inherited Parkinson’s disease is most often due to the LRRK2 mutation. While this mutation has been well-studied, research has been hindered by the lack of high-quality LRRK2 antibodies available.
MJFF organized primary characterization of the LRRK2 molecule which, in tandem with available data on rabbit monoclonal antibodies used for Parkinson’s disease research, has led to the emergence of three clones of rabbit monoclonal antibodies that have achieved the best performance parameters. These antibodies were selected for distribution via Abcam.
LRRK2 antibodies are critical in helping move Parkinson's research forward. The three unique clones chosen for initial release were identified based on several months of testing by our large network of PD researchers... we are excited that they [Abcam] will continue to help MJFF remove barriers to developing Parkinson's therapies,"
Dr. Mark Frasier, Vice President of Research Programs at MJFF.
Custom Monoclonal Antibody Development
When MJFF identified a need for quality Parkinson’s disease research tools to enhance their current portfolio they approached Abcam to sponsor the custom production of RabMAb® primary antibodies to key Parkinson’s disease targets.
Our custom solutions use antibodies designed to maximize the likelihood of success in research and diagnostic programs. From recombinant antibodies that can detect new biomarkers to antibodies that have performed consistently with high degrees of sensitivity in diagnostic tests, we have the solution you are looking for.
Abcam’s Unique Offering
Abcam has a long and trusted record in producing specific antibodies to a wide variety of protein targets across a broad range of research areas and applications such as IHC and CyTOF.
Abcam’s discovery platform boasts a robust IP that makes it easy to take the same clone in the lab into the clinic.
For rapid and reliable screening, Abcam has the tools to run bespoke assay cascades and perform custom library screening. HTRF, fluorescence assays, IC50, PK/PD, functional assays and reporter assays are some of what we offer.
The Abcam team has extensive industry experience, which means that users can get support at any stage of the program. From antigen design to the supply of GMP/IVD supply – we will take care of everything.
Confidence when it counts
With our tried-and-tested multiplatform approach, that includes the proprietary NGS-rabbit monoclonal platform, alongside our unique offering, we are confident that we are the best option for you.
Confidentiality is of great importance to us. When designing and providing customized solutions, we deal with many commercial partners that have technologies and projects that need to be kept confidential. For this reason, we have put in place multiple firewalls and protective devices to keep its partners and their projects strictly private.
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Our mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Our ambition is to become the most influential life science company for researchers worldwide.
We continue to identify the biological pathways of greatest interest to our consumers and continuously strive to provide products of the highest quality with increased specificity, reproducibility and sensitivity. At the same time, through investment and acquisition, we are expanding into new markets, identifying new technologies and applications while moving into new geographic regions, thereby driving sustainable growth.
Headquartered in Cambridge, UK, we employ over 900 people across twelve locations serving researchers in more than 100 countries.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.